SITI Promotes Hong Kong's Innovation Collaboration During Visit to Stockholm

SITI continues visit to Sweden

The Secretary for Innovation, Technology and Industry, Professor Sun Dong, continued his visit to Stockholm, Sweden on May 12 (Stockholm time).

In the morning, Professor Sun visited the Uppsala University and met with the Vice-Chancellor, Professor Anders Hagfeldt. The Uppsala University is one of the leading comprehensive research universities in Sweden, actively promoting global sustainable development and technological innovation in recent years. Professor Sun invited the University to participate in the establishment of Life and Health Technology Research Institute in Hong Kong.

Professor Sun was then briefed on the Uppsala Innovation Centre and STUNS, as well as the development of various start-ups nurtured by the University, gaining an in-depth understanding of how the local innovation system promotes close industry-academia-research collaboration, and drives the transformation and commercialisation of research and development (R&D) outcomes. The participants also exchanged views on the future collaboration in R&D, application, and commercialisation of technologies. STUNS is a foundation focusing on promoting collaboration among universities, business and society in the Uppsala region.

Professor Sun then departed for Helsinki, Finland for his visit. Upon arrival, he met with the Chargé d'Affaires a.i. of the Embassy of the People's Republic of China in the Republic of Finland, Mr Chen Huixin, to introduce the latest progress of the Hong Kong Special Administrative Region Government in promoting innovation and technology (I&T) development, as well as the related work on fully propelling the development of the Northern Metropolis and accelerating the construction of the Hong Kong Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. He also elaborated on Hong Kong's continuous efforts in actively integrating into the overall development of the country and serving the nation's I&T development.

Professor Sun will continue his visit to Finland on May 13 (Helsinki time).

The Secretary for Innovation, Technology and Industry, Professor Sun Dong (left), met with the Chargé d'Affaires a.i. of the Embassy of the People's Republic of China in the Republic of Finland, Mr Chen Huixin (right), in Helsinki, Finland on May 12 (Helsinki time). Source: HKSAR Government Press Releases

The Secretary for Innovation, Technology and Industry, Professor Sun Dong (front row, sixth right), visited the Uppsala University in Stockholm, Sweden on May 12 (Stockholm time). Source: HKSAR Government Press Releases

The Secretary for Innovation, Technology and Industry, Professor Sun Dong (right), was briefed on the Uppsala Innovation Centre and STUNS in Stockholm, Sweden on May 12 (Stockholm time). The participants also exchanged views on the future collaboration in research and development, application, and commercialisation of technologies. Source: HKSAR Government Press Releases

The Secretary for Innovation, Technology and Industry, Professor Sun Dong (left), visited the Uppsala University and met with the Vice-Chancellor, Professor Anders Hagfeldt (right), in Stockholm, Sweden on May 12 (Stockholm time). Source: HKSAR Government Press Releases

DH and Hong Kong Customs carry out joint operation to crack down on illegal online sale and illegal import of controlled anti-obesity injection

To combat the illegal online sale and illegal import of controlled anti-obesity injections, the Department of Health (DH) and Hong Kong Customs carried out a joint enforcement operation yesterday (May 12) in Tin Shui Wai, arresting a 31-year-old woman suspected of illegally selling Part 1 poison and an unregistered pharmaceutical product, and importing a pharmaceutical product not under and in accordance with a licence.

Following up on a complaint, the DH and Hong Kong Customs purchased two boxes of an anti-obesity injection (see photos) from the woman in question via an online social media platform. The product packaging indicated in Japanese that it contains tirzepatide, a substance classified as Part 1 poison under the Pharmacy and Poisons Ordinance (Cap. 138) (PPO). The product is suspected to be an unregistered pharmaceutical product in Hong Kong.

The DH and Hong Kong Customs will continue to investigate the case, and the arrested person has been released on bail pending further investigation.

Tirzepatide is used for the treatment of obesity, and its side effects include hair loss, nausea and diarrhoea. Medicines containing tirzepatide should be used under a doctor's direction and must be supplied on the premises of an Authorized Seller of Poisons (commonly known as a pharmacy) under the supervision of a registered pharmacist upon a doctor's prescription.

The DH strongly urged members of the public not to self-purchase or consume products of doubtful composition or from unknown sources. Purchasing controlled medicines (including anti-obesity injections) online poses health risks. Besides the lack of a doctor's assessment of an individual's health condition, it is difficult to ascertain the legitimate source of the drugs. It is also impossible to know whether the drugs were properly stored during transportation (especially for drugs requiring cold-chain storage). This leaves their safety, quality and efficacy unguaranteed.

The DH also reminded the public that selling medicines controlled under the PPO illegally, regardless of the sales channel (including online sales platforms, instant messaging applications or social media), carries criminal liability. Do not risk breaking the law.

According to the PPO, all pharmaceutical products must be registered with the Pharmacy and Poisons Board of Hong Kong before they can be legally sold in the market. Additionally, pharmaceutical products containing Part 1 poisons could only be sold at the registered premises of a pharmacy under the supervision of a registered pharmacist. If any contravention of the law is suspected, the DH will follow up and carry out enforcement action. After seeking advice from the Department of Justice, prosecutions against relevant persons may be initiated. Illegal sale or possession of unregistered pharmaceutical products or Part 1 poisons is a criminal offence. The maximum penalty for each offence is a fine of $100,000 and two years' imprisonment.

Hong Kong Customs reminded the public that under the Import and Export Ordinance (Cap. 60), import or export of all controlled items(including pharmaceutical products and medicines) must be accompanied by a valid licence issued by the relevant authorities. Any person who brings any controlled item into/out of Hong Kong (whether in person, by post, or through purchasing agents or consolidated consignments) without a valid licence may be prosecuted, in addition to the confiscation of the subject item. The maximum penalty upon conviction is a fine of $500,000 and imprisonment for two years.

The DH reminded the public that all registered pharmaceutical products should carry a Hong Kong registration number on the package in the format of "HK-XXXXX". The safety, quality and efficacy of unregistered pharmaceutical products are not guaranteed.

Weight control should be achieved through a balanced diet and appropriate exercise. The public should consult healthcare professionals before consuming any medication for weight control. They may visit the website of the Drug Office of the DH for "Health message on overweight problem and slimming products" for information.

DH and Hong Kong Customs carry out joint operation to crack down on illegal online sale and illegal import of controlled anti-obesity injection Source: HKSAR Government Press Releases

DH and Hong Kong Customs carry out joint operation to crack down on illegal online sale and illegal import of controlled anti-obesity injection Source: HKSAR Government Press Releases